The global clopidogrel market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to accelerate the growth of the market during the forecast period include the increased demand for clopidogrel among patients who are suffering from CVD and related problems. Moreover, the changing lifestyle and increase in the number of patients related to cardiovascular diseases among the emerging economies in the Asia Pacific region are further expected to drive the market growth during the forecast period. Moreover, the patent expiry of clopidogrel drugs is anticipated to open possibilities for various pharmaceutical companies to venture into the production of clopidogrel drugs.
Clopidogrel is an antiplatelet agent of thienopyridine, which is primarily used to prevent blood clots and support against CVD problems associated with blood clotting. The medications used for inhibiting blood clots after a recent heart stroke also involves the use of clopidogrel, which is a white-coloured powder that is insoluble in water at neutral pH, however, freely soluble at pH1. Sold under the brand name Plavix, and marketed by Sanofi and Bristol-Myers Squibb, the demand for clopidogrel is escalating owing to the increasing number of heart attack cases across the globe. Furthermore, several other organizations such as Roxane Laboratories, Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Apotex Inc., have gained approval for marketing clopidogrel 75mg. Clopidogrel is also used with aspirin to treat worsening chest pain and keep blood vessels open and prevent blood clots after certain heart-related operations. According to the World Heart Federation, nearly 15 million people suffer from heart attack or related problems globally. Out of these, roughly six million of these patients die while another five million are disabled permanently. This vast patient base is the primary factor that will sustain the demand for clopidogrel during the forecast period.
To Request a Sample of our Report on Clopidogrel Market: https://www.omrglobal.com/request-sample/clopidogrel-market
Market Coverage
- The market number available for – 2021-2030
- Base year- 2023
- Forecast period- 2023-2030
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Sanofi S.A., Bristol Myers Squibb Co., and Sun Pharmaceutical Industries Ltd., among others.
Clopidogrel Market Report by Segment
By Type
- 25 mg
- 75 mg
- 300 mg
By Application
- Hospitals
- Private Clinics
- Retail Pharmacies
- Online Pharmacies
- Others
A full Report of Clopidogrel Market is Available @ https://www.omrglobal.com/industry-reports/clopidogrel-market
Clopidogrel Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/clopidogrel-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
